tickrz reports
tickrz rank
B
Amgen Inc (AMGN)
Healthcare | Drugs
186.56  -0.14%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankB / 194Warren Buffett RankB / 137
Pure Value RankC / 242Dividend RankC / 230
Moat RankA / 8Financial Strength RankA / 45
Growth RankA / 53Momentum RankC / 369
AMGN vs DRUGS SECTOR & S&P 500
VALUATION
AMGNSECTORS&P 500
P/E RATIO16.9335.719.28
EV/EBITDA RATIO10.2425.111.77
P/S RATIO67.12.03
P/B RATIO4.368.73.09
QUALITY
RETURN ON EQUITY26.43%16.98%13.82%
RETURN ON CAPITAL31.06%26.23%10.04%
NET MARGIN34.04%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.29%
PAYOUT RATIO38.99%
3 YR DIVIDEND GROWTH28.62%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
8 OUT OF 9
DEBT-TO-EQUITY111%
INTEREST COVERAGE7.51x
CURRENT RATIO6.2
GROWTH
5 YR EPS GROWTH20.44%
5 YR SPS GROWTH7.65%
5 YR BPS GROWTH11.09%
About tickrz
Key Concepts
Great Investors
Amgen Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank B / 194
Amgen Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking C / 242Warren Buffett ranking B / 137
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Amgen Inc's valuation score is comprised of a P/E ratio of 16.9x, a P/B ratio of 4.4x, a P/S ratio of 6x, and an EV/EBITDA ratio of 10.2x. Amgen Inc ranks 242 out of the S&P 500 constituents on valuation--a relatively weak score.Amgen Inc ranks 137 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Amgen Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

quality
moat A / 8financial strength A / 45
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Amgen Inc appears to have a durable competitive advantage within the Healthcare sector. Amgen Inc has a Piotroski F Score of 8 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 7.51x, a debt/equity ratio of 111% and a Moat Rank of 8 translate to a strong Financial Strength score.


momentum C / 369
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -1.51% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 369. Based on its 12 month stock performance, Amgen Inc will not appeal to momentum investors.

yield C / 230
value + yield
Shares currently yield 2.29%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Amgen Inc ranks 230 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth A / 53
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 20.4% 5 year annualized EPS growth, 7.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 11.1% speak to its impressive growth ranking.

Amgen Inc (AMGN)
Healthcare | Drugs
186.56  -0.14%


tickrz rank
B
VALUATION RATIOS
P/E Ratio16.93x
P/B Ratio4.36x
P/S Ratio6x
EV/EBITDA Ratio10.24x
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.29%
PAYOUT RATIO38.99%
3 YR DIVIDEND GROWTH28.62%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
8 OUT OF 9
DEBT-TO-EQUITY111%
INTEREST COVERAGE7.51x
CURRENT RATIO6.2
MOAT
ROE26.43%
ROIC31.06%
Net Margin34.04%
GROWTH
5 YR EPS GROWTH20.44%
5 YR SPS GROWTH7.65%
5 YR BPS GROWTH11.09%

TICKRZ RANK
Amgen Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Amgen Inc's valuation score is comprised of a P/E ratio of 16.9x, a P/B ratio of 4.4x, a P/S ratio of 6x, and an EV/EBITDA ratio of 10.2x. Amgen Inc ranks 242 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Amgen Inc ranks 137 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Amgen Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Amgen Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Amgen Inc has a Piotroski F Score of 8 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 7.51x, a debt/equity ratio of 111% and a Moat Rank of 8 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -1.51% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 369. Based on its 12 month stock performance, Amgen Inc will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.29%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Amgen Inc ranks 230 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 20.4% 5 year annualized EPS growth, 7.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 11.1% speak to its impressive growth ranking.